ESMO 2024
Stay up-to-date with the latest coverage of the ESMO 2024 Congress.
Dr. Grande discusses the importance of durvalumab for shifting the MIBC treatment landscape.
Dr. Jensen highlights the single-arm trial design and TOMBOLA's use of ctDNA.
Dr. Hussain provides his thoughts on how and why to increase worldwide attention on rare forms of bladder cancer.
Dr. Hussain summarizes his presentation on rare and predominant variant histologies in bladder cancer.
Dr. Galsky discusses the value of HER2 status and the promising 75% ORR from the phase 2 trial.
Additional evidence for neoadjuvant therapy for patients undergoing RC, ineligible for neoadjuvant platinum-based chemo.
SPLASH continues to show benefit for PSMA RLT in mCRPC and adds to this consideration in the pre-chemotherapy setting.
The TiNivo-2 trial found that a tivozanib-nivolumab combination therapy did not improve outcomes over tivozanib alone.
The final results of the CONTACT-02 trial show favorable, but not statistically significant, benefit for cabo/atezo in mCRPC.
Perioperative durvalumab with NAC offers “meaningful improvement” in EFS and OS for patients with cisplatin-ineligible ...
Results of SunRISe-1 provide support for TAR-200 monotherapy in patients with BCG-unresponsive high-risk NMIBC.
The combination of ipilimumab/nivolumab may be a new standard in some subgroups of patients with metastatic nccRCC.
Drs. Necchi, Tawagi discuss the interim analysis of SunRISe-4 - TAR-200 plus cetrelimab or cetrelimab alone in MIBC patients.
Drs. Necchi and Tawagi highlight some the challenges in penile cancer, including "suboptimal" neoadjuvant, adjuvant options.
Dr. Pobel offers an overview of the ancillary study of the PEACE-1 trial, including how immunohistochemistry was used.
Drs. Barata and Tawagi provide updates in nccRCC, including SAMETA, PAPMET2, SUNNIFORECAST, and updated NCCN guidelines.
ctDNA testing may help identify patients with bladder cancer who would benefit from early post-cystectomy immunotherapy.
EV/pembro may offer first-line PFS and OS benefit in patients with la/mUC, regardless of Nectin-4 expression.
A phase 2 study highlights the “encouraging” antitumor activity from futibatinib plus pembrolizumab for patients with ...
Disitamab vedotin plus pembrolizumab shows promising efficacy, manageable safety in HER2+ aUC, with a 61.1% response rate.
Prognostic and predictive phenotypic biomarkers have been identified for rPFS and OS in de novo mCSPC.
The addition of nivo to trimodality therapy may improve RFS in patients with non-metastatic muscle-invasive bladder cancer.
PFS was improved with nivolumab plus cabozantinib.
In patients with pretreated UC, BL-B01D1 demonstrated manageable safety with encouraging antitumor activity.
Enfortumab vedotin plus pembrolizumab showed consistent PFS and OS benefit across all subgroups.
The AMBASSADOR study demonstrated a significant improvement in disease-free survival for pembrolizumab.
The Two Onc Docs provide a brief overview of the the urothelial carcinoma, RCC, and prostate cancer presentations of note
Dr. Armstrong previews updates related to STAMPEDE, ARANOTE, LITESPARK-005, AMBASSADOR, and others.
In anticipation of ESMO, Dr. Katy Beckermann previews various clinical trials and studies to be presented in kidney cancer.
Advertisement
GU Oncology Now delivers the latest news in clinical trials, conference coverage, and more, highlighting advancements in genitourinary oncology treatments and tech.
Get conference updates straight to your inbox.
Advertisement
